XanaMIA pivotal trial completes all patient visits — topline results confirmed for November
Actinogen Medical has confirmed that the final participant visit in its XanaMIA Phase 2b/3 Alzheimer’s disease trial was completed in the USA on 22 September 2026, with topline results now on track for November 2026. The milestone marks the end of patient-level data collection for a pivotal trial — not a preliminary study — making the November readout a binary, high-consequence catalyst for the company.
The trial enrolled 247 participants across Australia (45%) and the United States (55%), and is now closed to recruitment. With all patient visits complete, Actinogen’s focus turns entirely to data finalisation and preparation for the November release.
When big ASX news breaks, our subscribers know first
What is XanaMIA and how does Xanamem work?
Xanamem (emestedastat) is an oral, once-daily pill designed to inhibit 11β-HSD1, the enzyme responsible for cortisol synthesis inside brain cells. By targeting this enzyme, Xanamem aims to reduce chronically elevated “stress hormone” levels in the brain without disrupting the body’s normal adrenal cortisol production, which is essential for everyday physiological function.
The rationale is grounded in the neurotoxic role of cortisol in Alzheimer’s disease (AD). Chronically elevated brain cortisol is associated with disease progression and is toxic to brain cells. Xanamem is a first-in-class agent for this mechanism and has been studied in more than 500 volunteers and patients across eight clinical trials.
What distinguishes XanaMIA’s design is its use of pTau181, a clinically validated blood biomarker, to confirm Alzheimer’s diagnoses. This approach replaces more complex methods such as amyloid brain scans or cerebrospinal fluid sampling, selecting participants with a more progressive disease course to maximise the trial’s statistical power to detect a treatment effect.
Key design features of the XanaMIA trial include:
- 247 participants enrolled; trial now closed to recruitment
- 36-week double-blind, randomised, placebo-controlled treatment phase
- Primary endpoint: CDR-SB (Clinical Dementia Rating scale – Sum of Boxes)
- pTau181 blood biomarker used to confirm Alzheimer’s diagnosis
- Open-label extension phase (XanaMIA-OLE) commenced March 2026
Participant profile and what it signals about trial power
The enrolled participants’ baseline characteristics are comparable to those reported in other trials of patients with mild to moderate AD. This alignment supports the validity of any treatment effect the trial may detect and reflects a rigorous enrolment approach. Published evidence from the Phase 2a patient population, where a large treatment benefit for Xanamem was seen (Taylor et al. 2024), used a similar diagnostic profile, lending additional scientific context to the trial’s design choices.
| Characteristic | Value | Relevance |
|---|---|---|
| Average age | 75 years | Consistent with mild to moderate AD trial populations |
| Female participants | 49% | Near-equal sex distribution supports generalisability |
| ApoE4 carriers | 66% | High enrichment for the primary genetic risk factor for AD |
| Mean pTau181 | 2.6 (SD 1.3) pg/mL | Confirms biomarker-positive, progressive disease at baseline |
| Mean CDR-SB | 4.3 (SD 2.0) points | Aligns with other major AD studies; anchors primary endpoint |
The trial has also passed an independent Data Monitoring Committee (DMC) safety and efficacy futility review, a meaningful de-risking milestone that indicates the trial met predefined safety thresholds and that continuation was supported on efficacy grounds.
The third consecutive DMC safety clearance, delivered in June 2026, reviewed data from all 247 participants and resulted in no protocol amendments, adding further weight to the safety profile Xanamem has built across more than 500 volunteers and patients.
November readout — what investors should watch
The November topline results represent the defining near-term catalyst for ACW. As a Phase 2b/3 pivotal trial, the readout will carry significantly greater regulatory and commercial weight than an earlier-stage signal study, and the outcome is expected to shape the company’s near-term trajectory.
Actinogen’s Chief Medical Officer, Dr Dana Hilt, framed both the data priority and the regulatory planning dimension in comments accompanying the announcement:
Dr Dana Hilt, Chief Medical Officer
“Xanamem is a unique oral therapy with the potential to become a transformational treatment option for patients and their families living with Alzheimer’s disease. Our key focus is to finalise high-quality data from the XanaMIA pivotal trial for release in November while planning streamlined pathways to the fastest possible regulatory approvals for Xanamem.”
The quote signals that regulatory pathway planning is already under way concurrently with data preparation, though no approvals have been secured and the CMO’s reference is to planning pathways rather than outcomes confirmed.
Separately, the XanaMIA-OLE (open-label extension) commenced in March 2026 and is open to all former and current XanaMIA participants. Under the OLE, participants receive active Xanamem 10 mg once daily for up to 25 months, providing an ongoing stream of safety and efficacy data regardless of the topline result.
The XanaMIA open-label extension, which commenced on 31 March 2026 with its first participant, is also generating long-term CDR-SB, cognition, and activities of daily living data that can feed directly into future regulatory marketing applications if topline results prove positive.
The broader clinical context is also relevant. Alzheimer’s disease represents one of the largest areas of unmet medical need globally. An oral, once-daily, first-in-class cortisol-targeting agent would occupy a distinct therapeutic space from the amyloid-targeting therapies currently approved, potentially addressing patients for whom existing treatments are unsuitable or ineffective. With all patient visits now complete and the data finalisation phase under way, November 2026 represents a clearly defined, time-bounded readout for investors watching the ACW story.
Don’t Miss the Next ASX Healthcare Catalyst
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already ahead of the market and never miss a high-stakes readout again. Click the “Free Alerts” button at Big News Blast to receive alerts the moment market-moving healthcare news breaks.